Cargando…

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment

Triple-negative breast cancer (TNBC) shows limited therapeutic efficacy. PARP inhibitor has been approved to treat advanced BRCA-mutant breast cancer but shows high resistance. Therefore, the development of new therapeutics that sensitize TNBC irrespective of BRCA status is urgently needed. The nedd...

Descripción completa

Detalles Bibliográficos
Autores principales:	Misra, Shrilekha, Zhang, Xiaoli, Wani, Nissar Ahmad, Sizemore, Steven, Ray, Alo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055543/ https://www.ncbi.nlm.nih.gov/pubmed/32166000 http://dx.doi.org/10.18632/oncotarget.27485

Ejemplares similares

Broad and potent antiviral activity of the NAE inhibitor MLN4924
por: Le-Trilling, Vu Thuy Khanh, et al.
Publicado: (2016)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016)

The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance
por: Du, Meng-ge, et al.
Publicado: (2021)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

Neddylation inhibitor MLN4924 suppresses cilia formation by modulating AKT1
por: Mao, Hongmei, et al.
Publicado: (2019)

Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy
por: Aubry, Arthur, et al.
Publicado: (2020)

Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells
por: Lan, Huiyin, et al.
Publicado: (2016)

The novel protective role of P27 in MLN4924-treated gastric cancer cells
por: Zhang, Q, et al.
Publicado: (2015)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

Inhibiting Neddylation with MLN4924 Suppresses Growth and Delays Multicellular Development in Dictyostelium discoideum
por: Huber, Robert J., et al.
Publicado: (2021)

The potential oncogenic and MLN4924-resistant effects of CSN5 on cervical cancer cells
por: Zhang, Huilin, et al.
Publicado: (2021)

MLN4924 inhibits cell proliferation by targeting the activated neddylation pathway in endometrial carcinoma
por: Liu, Huanrong, et al.
Publicado: (2021)

MLN4924 Promotes Self-Renewal of Limbal Stem Cells and Ocular Surface Restoration
por: Li, Qingjian, et al.
Publicado: (2023)

MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2016)

The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice
por: Yu, Huilin, et al.
Publicado: (2022)

Neddylation inhibitor MLN4924 sensitizes head and neck squamous carcinoma cells to (S)-10-hydroxycamptothecin
por: Gu, Shanshan, et al.
Publicado: (2023)

MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma
por: Ho, I-Lin, et al.
Publicado: (2015)

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
por: Wang, Xiaofang, et al.
Publicado: (2016)

Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus
por: Chang, Pey-Jium, et al.
Publicado: (2017)

Cardioprotective effect of MLN4924 on ameliorating autophagic flux impairment in myocardial ischemia-reperfusion injury by Sirt1
por: Zhang, Ji, et al.
Publicado: (2021)

Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
por: Xu, G. Wei, et al.
Publicado: (2014)

Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment
por: Filippova, Natalia, et al.
Publicado: (2018)

The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth via triggering autophagy
por: Lv, Yongzhu, et al.
Publicado: (2018)

Circadian clock components RORα and Bmal1 mediate the anti-proliferative effect of MLN4924 in osteosarcoma cells
por: Zhang, Shuju, et al.
Publicado: (2016)

The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling
por: Han, Suji, et al.
Publicado: (2019)

The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme
por: Yang, Dong, et al.
Publicado: (2012)

Correction: Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
Publicado: (2014)

The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation
por: Andérica-Romero, Ana Cristina, et al.
Publicado: (2016)

The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia
por: Han, Kun, et al.
Publicado: (2016)

MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma
por: Tong, Shuai, et al.
Publicado: (2017)

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors
por: Bahjat, Mahnoush, et al.
Publicado: (2019)

Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
por: Xiong, Shida, et al.
Publicado: (2022)

Correction for Yu et al., The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice
Publicado: (2022)

MLN4924 Exerts a Neuroprotective Effect against Oxidative Stress via Sirt1 in Spinal Cord Ischemia-Reperfusion Injury
por: Yu, Sifei, et al.
Publicado: (2019)

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
por: Visconte, Valeria, et al.
Publicado: (2015)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers
por: Lan, Chungen, et al.
Publicado: (2022)

The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1(+) subgroup of multiple myeloma cells for TNF-induced cell death
por: El-Mesery, Mohamed, et al.
Publicado: (2019)

MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis
por: Wu, Meng-Huang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u2rpjt9uvgrgkrua9b00c2tfsv